AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health’s 2026 Patient ...

Canaccord analyst Sumant Kulkarni raised the firm's price target on AtaiBeckley to $15 from $14 and kept a ‘Buy’ rating on ...

In April 2026, AtaiBeckley Inc. reported expanded Phase 2a data showing its oral R-MDMA candidate EMP-01 produced clinically ...

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic ...

Shares of psychedelic drug developers rose after Trump signed an executive order directing health regulators to speed up ...

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best multibagger penny stocks to invest in. On March 27, Deutsche Bank initiated coverage of AtaiBeckley Inc. (NASDAQ:ATAI) with a Buy rating and a $12 ...

Psychedelic-related stocks rose in premarket trading after President Donald Trump signed an executive order aimed at accelerating research and expanding access to substances used abroad to treat ...

U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic ...

The directive is expected to lead to fewer legal hurdles for psychedelic studies, increased funding, and potentially ...

Enveric Biosciences (ENVB) stock exploded 160%+ after Trump's executive order to accelerate psychedelic drug reviews and $50M ...

Some psychedelic stocks can rally after the executive order on the use of the this type of drug for mental health, ...